Avid Bioservices Inc (CDMO)

[biopharm]

Janice M. Reichert, 8 ,*

lots of names over the years, but I like Paul Reichert, working on translational studies surrounding NASA, it is the 1% that makes the difference and PS Targeting in deep space? Most certainly. Pay attention to interferon that is mentioned and we already know that PS Targeting Bavituximab could replace interferon, according to Joe Shan

http://www.merck.com/about/our-people/paul-reichert.html

----------------------------------------------------------

Sir Greg Winters on the list as well and hmmm, I see that Alex Duncan of Agenus spent many hours in that lab

anyhow.... just so all can see Joe Shan did say this and yes, PS Targeting just starting a HepC trial now again, after all these years and now, biomarkers will be the key to many FDA approvals. Don't let the 12 week trial below that stopped fool you, it worked... thought it was not allowed enough time and now-- biomarkers will be used during the initial weeks and will likely be approved in no time.

"Bavituximab used as a single agent has demonstrated a consistent, acceptable safety profile in three Phase I HCV trials to date, and we have seen enhanced antiviral activity when using bavituximab in combination with the antiviral agent ribavirin in several preclinical viral disease models," said Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals. "Our recently initiated randomized Phase II trial will assess early virology response of genotype 1 HCV patients after 12 weeks of therapy combining bavituximab with ribavirin as a potential alternative to the current interferon-based regimen."

http://ir.peregrineinc.com/releasedetail.cfm?releaseid=561545